Feixiang Wang, Guoxin Huang, Yuqing Luo, Kaixin Xiong, Ying Liu, Yao Wang
{"title":"循环免疫细胞与淋巴瘤的因果关系:孟德尔随机化研究","authors":"Feixiang Wang, Guoxin Huang, Yuqing Luo, Kaixin Xiong, Ying Liu, Yao Wang","doi":"10.1515/med-2024-0984","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Malignant lymphoma (ML) is a group of malignant tumors originating from the lymphatic hematopoietic system. Previous studies have found a correlation between circulating immune cells and ML. Nonetheless, the precise influence of circulating immune cells on ML remains uncertain.</p><p><strong>Methods: </strong>Based on publicly available genetic data, we explored causal associations between 731 immune cell signatures and ML risk. A total of four types of immune signatures, median fluorescence intensities, relative cell, absolute cell, and morphological parameters were included. Primary analysis was performed using inverse variance weighting (IVW) to assess the causal relationship between circulating immune cells and the risk of ML. Sensitivity analysis was conducted using Cochran's <i>Q</i> test, the Mendelian randomization Egger regression intercept test, and leave-one-out analysis.</p><p><strong>Results: </strong>ML had a statistically significant effect on immunophenotypes. Twenty-three immunophenotypes were identified to be significantly associated with Hodgkin lymphoma risk through the IVW approach, and the odds ratio values of CD64 on CD14<sup>-</sup> CD16<sup>+</sup> monocyte [2.31, 95% confidence interval (CI) = 1.41-3.79, <i>P</i>1 = 0.001], IgD<sup>+</sup> CD24<sup>+</sup> B-cell %lymphocyte (2.06, 95% CI = 1.13-3.79, <i>P</i>1 = 0.018), B-cell %lymphocyte (1.94, 95% CI = 1.08-3.50, <i>P</i>1 = 0.027), CD24<sup>+</sup> CD27<sup>+</sup> B-cell %lymphocyte (1.68, 95% CI = 1.03-2.74, <i>P</i>1 = 0.039), and CD14<sup>+</sup> CD16<sup>-</sup> monocyte %monocyte (1.60, 95% CI = 1.15-2.24, <i>P</i>1 = 0.006) ranked in the top five. Eleven immunophenotypes were identified to be significantly associated with non-Hodgkin lymphoma risk, CD86 on granulocyte (2.35, 95% CI = 1.18-4.69, <i>P</i>1 = 0.015), CD28<sup>-</sup>CD8<sup>+</sup> T-cell absolute count (1.76, 95% CI = 1.03-2.99, <i>P</i>1 = 0.036), CCR2 on myeloid dendritic cell (CD24<sup>+</sup> CD27<sup>+</sup> B cell, 95% CI = 1.02-1.66, <i>P</i>1 = 0.034), CD3 on effector memory CD8<sup>+</sup> T cell (1.29, 95% CI = 1.02-1.64, <i>P</i>1 = 0.012), and natural killer T %lymphocyte (1.28, 95% CI = 1.01-1.62, <i>P</i>1 = 0.046) were ranked in the top five.</p><p><strong>Conclusion: </strong>This study presents compelling evidence indicating the correlation between circulating immune cells and lymphoma, thus providing guidance for future clinical research.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"19 1","pages":"20240984"},"PeriodicalIF":1.7000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249620/pdf/","citationCount":"0","resultStr":"{\"title\":\"Causal association of circulating immune cells and lymphoma: A Mendelian randomization study.\",\"authors\":\"Feixiang Wang, Guoxin Huang, Yuqing Luo, Kaixin Xiong, Ying Liu, Yao Wang\",\"doi\":\"10.1515/med-2024-0984\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Malignant lymphoma (ML) is a group of malignant tumors originating from the lymphatic hematopoietic system. Previous studies have found a correlation between circulating immune cells and ML. Nonetheless, the precise influence of circulating immune cells on ML remains uncertain.</p><p><strong>Methods: </strong>Based on publicly available genetic data, we explored causal associations between 731 immune cell signatures and ML risk. A total of four types of immune signatures, median fluorescence intensities, relative cell, absolute cell, and morphological parameters were included. Primary analysis was performed using inverse variance weighting (IVW) to assess the causal relationship between circulating immune cells and the risk of ML. Sensitivity analysis was conducted using Cochran's <i>Q</i> test, the Mendelian randomization Egger regression intercept test, and leave-one-out analysis.</p><p><strong>Results: </strong>ML had a statistically significant effect on immunophenotypes. Twenty-three immunophenotypes were identified to be significantly associated with Hodgkin lymphoma risk through the IVW approach, and the odds ratio values of CD64 on CD14<sup>-</sup> CD16<sup>+</sup> monocyte [2.31, 95% confidence interval (CI) = 1.41-3.79, <i>P</i>1 = 0.001], IgD<sup>+</sup> CD24<sup>+</sup> B-cell %lymphocyte (2.06, 95% CI = 1.13-3.79, <i>P</i>1 = 0.018), B-cell %lymphocyte (1.94, 95% CI = 1.08-3.50, <i>P</i>1 = 0.027), CD24<sup>+</sup> CD27<sup>+</sup> B-cell %lymphocyte (1.68, 95% CI = 1.03-2.74, <i>P</i>1 = 0.039), and CD14<sup>+</sup> CD16<sup>-</sup> monocyte %monocyte (1.60, 95% CI = 1.15-2.24, <i>P</i>1 = 0.006) ranked in the top five. Eleven immunophenotypes were identified to be significantly associated with non-Hodgkin lymphoma risk, CD86 on granulocyte (2.35, 95% CI = 1.18-4.69, <i>P</i>1 = 0.015), CD28<sup>-</sup>CD8<sup>+</sup> T-cell absolute count (1.76, 95% CI = 1.03-2.99, <i>P</i>1 = 0.036), CCR2 on myeloid dendritic cell (CD24<sup>+</sup> CD27<sup>+</sup> B cell, 95% CI = 1.02-1.66, <i>P</i>1 = 0.034), CD3 on effector memory CD8<sup>+</sup> T cell (1.29, 95% CI = 1.02-1.64, <i>P</i>1 = 0.012), and natural killer T %lymphocyte (1.28, 95% CI = 1.01-1.62, <i>P</i>1 = 0.046) were ranked in the top five.</p><p><strong>Conclusion: </strong>This study presents compelling evidence indicating the correlation between circulating immune cells and lymphoma, thus providing guidance for future clinical research.</p>\",\"PeriodicalId\":19715,\"journal\":{\"name\":\"Open Medicine\",\"volume\":\"19 1\",\"pages\":\"20240984\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249620/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1515/med-2024-0984\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2024-0984","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:恶性淋巴瘤(ML)是一组起源于淋巴造血系统的恶性肿瘤。以往的研究发现,循环免疫细胞与恶性淋巴瘤之间存在相关性。然而,循环免疫细胞对 ML 的确切影响仍不确定:方法:根据公开的基因数据,我们探讨了 731 个免疫细胞特征与 ML 风险之间的因果关系。共包括四种类型的免疫特征、荧光强度中值、相对细胞、绝对细胞和形态参数。使用逆方差加权法(IVW)进行了初步分析,以评估循环免疫细胞与 ML 风险之间的因果关系。使用科克兰Q检验、孟德尔随机化Egger回归截距检验和leave-one-out分析进行了敏感性分析:结果:ML 对免疫表型有显著的统计学影响。通过 IVW 方法确定了 23 种免疫表型与霍奇金淋巴瘤风险显著相关,CD14- CD16+ 单核细胞上 CD64 的几率比值[2.31,95% 置信区间(CI)= 1.41-3.79,P1 = 0.001]、IgD+ CD24+ B 细胞%淋巴细胞(2.06,95% CI = 1.13-3.79,P1 = 0.018)、B 细胞淋巴细胞百分比(1.94,95% CI = 1.08-3.50,P1 = 0.027)、CD24+ CD27+ B 细胞淋巴细胞百分比(1.68,95% CI = 1.03-2.74,P1 = 0.039)和 CD14+ CD16- 单核细胞%单核细胞(1.60,95% CI = 1.15-2.24,P1 = 0.006)排名前五。有 11 种免疫表型与非霍奇金淋巴瘤风险显著相关,粒细胞上的 CD86(2.35,95% CI = 1.18-4.69,P1 = 0.015)、CD28-CD8+ T 细胞绝对计数(1.76,95% CI = 1.03-2.99,P1 = 0.036)、髓样树突状细胞(CD24+ CD27+ B 细胞,95% CI = 1.02-1.66,P1 = 0.034)上的 CCR2、效应记忆 CD8+ T 细胞上的 CD3(1.29,95% CI = 1.02-1.64,P1 = 0.012)和自然杀伤 T %淋巴细胞(1.28,95% CI = 1.01-1.62,P1 = 0.046)排在前五位:本研究提供了令人信服的证据,表明循环免疫细胞与淋巴瘤之间存在相关性,从而为未来的临床研究提供了指导。
Causal association of circulating immune cells and lymphoma: A Mendelian randomization study.
Background: Malignant lymphoma (ML) is a group of malignant tumors originating from the lymphatic hematopoietic system. Previous studies have found a correlation between circulating immune cells and ML. Nonetheless, the precise influence of circulating immune cells on ML remains uncertain.
Methods: Based on publicly available genetic data, we explored causal associations between 731 immune cell signatures and ML risk. A total of four types of immune signatures, median fluorescence intensities, relative cell, absolute cell, and morphological parameters were included. Primary analysis was performed using inverse variance weighting (IVW) to assess the causal relationship between circulating immune cells and the risk of ML. Sensitivity analysis was conducted using Cochran's Q test, the Mendelian randomization Egger regression intercept test, and leave-one-out analysis.
Results: ML had a statistically significant effect on immunophenotypes. Twenty-three immunophenotypes were identified to be significantly associated with Hodgkin lymphoma risk through the IVW approach, and the odds ratio values of CD64 on CD14- CD16+ monocyte [2.31, 95% confidence interval (CI) = 1.41-3.79, P1 = 0.001], IgD+ CD24+ B-cell %lymphocyte (2.06, 95% CI = 1.13-3.79, P1 = 0.018), B-cell %lymphocyte (1.94, 95% CI = 1.08-3.50, P1 = 0.027), CD24+ CD27+ B-cell %lymphocyte (1.68, 95% CI = 1.03-2.74, P1 = 0.039), and CD14+ CD16- monocyte %monocyte (1.60, 95% CI = 1.15-2.24, P1 = 0.006) ranked in the top five. Eleven immunophenotypes were identified to be significantly associated with non-Hodgkin lymphoma risk, CD86 on granulocyte (2.35, 95% CI = 1.18-4.69, P1 = 0.015), CD28-CD8+ T-cell absolute count (1.76, 95% CI = 1.03-2.99, P1 = 0.036), CCR2 on myeloid dendritic cell (CD24+ CD27+ B cell, 95% CI = 1.02-1.66, P1 = 0.034), CD3 on effector memory CD8+ T cell (1.29, 95% CI = 1.02-1.64, P1 = 0.012), and natural killer T %lymphocyte (1.28, 95% CI = 1.01-1.62, P1 = 0.046) were ranked in the top five.
Conclusion: This study presents compelling evidence indicating the correlation between circulating immune cells and lymphoma, thus providing guidance for future clinical research.
期刊介绍:
Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.